UMass Chan Medical School licenses RNA-based Fragile X treatment approach using ASOs to QurAlis, moving a groundbreaking gene-targeted therapy closer to human clinical trials. The post UMass Chan Medical School Licenses RNA-Based Therapy to QurAlis, Advancing a New Era in Fragile X Treatment appeared first on FRAXA Research Foundation - Finding a Cure for Fragile X Syndrome.
